Intravenous methylprednisolone pulse therapy for acute posterior segment uveitis attacks in Behçet's disease

Annals of Ophthalmology

Volumn 39, Issue 3, 2007, Pages 194-197

  Yalçindag, F Nilûfer ^a   Can, Ertugrul ^a   Özdemir, Özden ^a  

^a ANKARA UNIVERSITY   (Turkey)

Author keywords

[No Author keywords available]

Indexed keywords

METHYLPREDNISOLONE;

ADULT; ARTICLE; BEHCET DISEASE; CLINICAL ARTICLE; CONTROLLED STUDY; DRUG EFFICACY; DRUG PULSE THERAPY; DRUG SAFETY; FEMALE; HUMAN; MALE; UVEITIS; VISUAL IMPAIRMENT;

ACUTE DISEASE; ADULT; ANTI-INFLAMMATORY AGENTS; BEHCET SYNDROME; BLOOD GLUCOSE; BLOOD PRESSURE; CATARACT; FEMALE; FLUSHING; FOLLOW-UP STUDIES; GLAUCOMA; HUMANS; MALE; METHYLPREDNISOLONE; MIDDLE AGED; PULSE THERAPY, DRUG; RETINAL DISEASES; RETROSPECTIVE STUDIES; TREATMENT OUTCOME; UVEITIS, POSTERIOR; WEIGHT GAIN;

EID: 36949033389     PISSN: 15304086     EISSN: None     Source Type: Journal    
DOI: 10.1007/s12009-007-0018-5     Document Type: Article

References (20)

1. Rizzi R, Bruno S, Dammacco R. Behçet's disease: an immune-mediated vasculitis involving vessels of all sizes. Int J Clin Lab Res 1997;27:225-232.
2. Colvard DM, Robertson DM, O'Duffy JD. The ocular manifestations of Behçet's disease. Arch Ophthalmol 1977;95:1813-1817.
3. Mamo JG. The rate of visual loss in Behçet's disease. Arch Ophthalmol 1970;84:451-452.
4. Forrester J, Okada A, BenEzra D, Ohno S. Posterior segment intraocular inflammation guidelines. Kugler, The Hague, 1998, pp. 127-133.
5. Kaklamani VG, Kaklamanis PG. Treatment of Behçet's Disease - an update. Semin Arthritis Rheum 2001;30:299-312.
6. Russel AI, Lawson WA, Haskara DO. Potential new therapeutic options in Behçet's Syndrome. BioDrugs 2001;15:25-35.
7. Sasamoto Y, Ohno S, Matsuda H. Studies on corticosteroid therapy in Vogt-Koyanagi-Harada disease. Ophthalmologica 1990;201:162-167.
8. Wakefield D, McClusky P, Penny R. Intravenous pulse methylprednisolone therapy in severe inflammatory eye disease. Arch Ophthalmol 1986;104:847-851.
9. Wakefield D, Jennings A, McCluskey PJ. Intravenous pulse methylprednisolone in the treatment of uveitis associated with multiple sclerosis. Clin Exp Ophthalmol 2000;28:103-106.
10. Reed JB, Morse LS, Schwab IR. High-dose intravenous pulse methylprednisolone hemisuccinate in acute Behçet retinitis. Am J Ophthalmol 1998;125:409-411.
11. Toker E, Kozakoǧlu H, Acar N. High dose intravenous steroid therapy for severe posterior segment uveitis in Behçet's disease. Br J Ophthalmol 2002;86:521-523.
12. International Study Group for Behçet's Disease. Criteria for diagnosis of Behçet's disease. Lancet 1990;335:1078-1080.
13. BenEzra D, Cohen E. Treatment and visual prognosis in Behçet's disease. Br J Ophthalmol 1986;70:589-592.
14. Hunder GG, Sheps SG, Allen GL, Joyce JW. Daily and alternate-day corticosteroid regimens in treatment of giant cell arteritis: comparison in a prospective study. Ann Intern Med 1957;82:613-618.
15. Melby JC. Clinical pharmacology of systemic corticosteroids. Ann Rev Pharmacol Toxicol 1977;17:511-527.
16. BenEzra D. Treatment of Behçet's disease. Ophthalmology 1989;1:1-4.
17. Stubbs SS, Morrell RM. Intravenous methylprednisolone sodium succinate: adverse reactions reported in association with immunosuppressive therapy. Transplant Proc 1973;5:1145-1146.
18. Garrett R, Paulus H. Complications of intravenous methylprednisolone pulse therapy, abstracted. Arthritis Rheum 1980;23:677.
19. Moses RE, McCormick A, Nickey W. Fatal arrhythmia after pulse methylprednisolone therapy. Ann Intern Med 1981;95:781-782.
20. Suchman AL, Condemi JJ, Leddy JP. Seizure after pulse therapy with methylprednisolone. Arthritis Rheum 1983;26:117.